NewVale Capital wraps up debut fund at $167m

The fund will accelerate the growth of pharmaceutical services companies.

  • The fund’s limited partners include university endowments, foundations, insurance companies, fund of funds and family offices
  • Strathmore Group LLC served as placement agent for NewVale
  • Founded in 2022, NewVale invests in the infrastructure of life sciences

NewVale Capital, a Boulder-based growth equity firm, has closed its inaugural fund at $167 million.

The fund will accelerate the growth of pharmaceutical services companies.

The fund’s limited partners include university endowments, foundations, insurance companies, fund of funds and family offices.

NewVale makes investments between $10 million and $50 million.

On the fundraising, Todd Holmes, founder and managing partner of NewVale, said in a statement, “While the science behind novel therapeutics has never been more promising, the pharmaceutical industry is undergoing a major evolutionary shift. To contend with its own rapid growth and formidable external pressures, the industry has been remodeling itself in ways that will make it sustainable for the decades ahead.”

Strathmore Group LLC served as placement agent for NewVale and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., provided legal counsel in connection with the fundraising.

Founded in 2022, NewVale invests in the infrastructure of life sciences. The firm has nearly $200 million in total under management.